Skip to main content

Research Repository

Advanced Search

Evaluation of the safety and immunogenicity of synthetic A?42 (AN1792) in patients with AD

Jones, R. W.; Bayer, A. J.; Wilkinson, D.; Paterson, K. R.; Jenkins, L.; Bullock, R.; Donoghue, S.; Millais, S. B.


R. W. Jones

A. J. Bayer

D. Wilkinson

K. R. Paterson

L. Jenkins

R. Bullock

S. Donoghue

S. B. Millais


Background: A?42-immunization reduces plaque burden and improves cognition in transgenic mouse models of Alzheimer disease (AD). This phase 1 study evaluated the safety, tolerability, and immunogenicity of AN1792 (human aggregated A?42) in patients with mild to moderate AD. Methods: Twenty patients were enrolled into each of four dose groups and randomly assigned to receive IM AN1792 (50 or 225 ?g) with QS-21 adjuvant (50 or 100 ?g) or QS-21 only (control) in a 4:1 active:control ratio on day 0 and at weeks 4, 12, and 24. Patients could receive up to four additional injections of a polysorbate 80 modified formulation at weeks 36, 48, 60, and 72. Safety, tolerability, immunogenicity, and exploratory evidence of efficacy were evaluated. Results: Treatment-related adverse events were reported in 19 (23.8%) patients, but no relationship was observed between AN1792 dose and incidence. One patient developed meningoencephalitis that was diagnosed after death (not directly related to study treatment) and 219 days after discontinuing from the study. Five deaths occurred during the study follow-up, but none was considered to be directly related to study treatment. During the period of the first four injections, 23.4% of AN1792-treated patients had a positive anti-AN1792 antibody titer (an anti-AN1792 antibody titer of ?1:1,000). This increased to 58.8% after additional injections with the modified formulation. Disability Assessment for Dementia scores showed less decline among active compared with control patients at week 84 (p = 0.002). No treatment differences were observed in three other efficacy measures. Conclusions: AN1792 + QS-21 elicited a positive antibody response to A?42 in more than half of this elderly study population.


Jones, R. W., Bayer, A. J., Wilkinson, D., Paterson, K. R., Jenkins, L., Bullock, R., …Millais, S. B. (2005). Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurology, 64(1), 94-101.

Journal Article Type Article
Publication Date Jan 11, 2005
Journal Neurology
Print ISSN 0028-3878
Publisher American Academy of Neurology
Peer Reviewed Not Peer Reviewed
Volume 64
Issue 1
Pages 94-101
Keywords AN1792, Alzheimer's, dementia
Public URL
Publisher URL

Downloadable Citations